GlassScriptPhysician profile
Lance Lavon Philyaw
NPI 1902300023
$641.84
in general payments reported to CMS, 2019-2025
16 companies · $78.53 in 2025
The $78.53 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.02 · 2021: $14.39 · 2022: $29.29 · 2023: $82.71 · 2024: $411 · 2025: $78.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $257.93 | 2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.54 | 2024 | Jardiance |
| Abbvie INC. | $44.36 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $30.17 | 2024-2025 | |
| Melinta Therapeutics, LLC | $27.45 | 2025 | Rezzayo |
| Abiomed | $22.32 | 2023 | Impella |
| Pfizer INC. | $22.04 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $17.38 | 2024 | Arcalyst |
| Tanabe Pharma America, INC. | $16.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.11 | 2023 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $15.00 | 2019 | |
| Amgen INC. | $14.39 | 2021 | |
| Mylan Specialty L.P. | $14.37 | 2023 | Yupelri |
| Viatris Specialty LLC | $13.47 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $12.50 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Philyaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.